Discussion on CELMoDs in NHL

CME

Next-Generation Non-Hodgkin Lymphoma Care: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 21, 2024

Expiration: August 20, 2025

Julio C Chavez
Julio C Chavez, MD, MS
Alan Skarbnik
Alan Skarbnik, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What is the primary rationale of promoting ubiquitination with CELMoDs in the treatment of NHL?

2.

What is the most common grade ≥3 AE associated with the CELMoDs golcadomide or avadomide?

3.

The ongoing phase III GOLSEEK-1 trial is investigating golcadomide + R-CHOP vs placebo + R-CHOP in which of the following patient populations?